These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 11981006

  • 1. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO.
    J Clin Oncol; 2002 May 01; 20(9):2344-52. PubMed ID: 11981006
    [Abstract] [Full Text] [Related]

  • 2. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct 01; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 3. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S.
    J Clin Oncol; 1996 Nov 01; 14(11):3018-25. PubMed ID: 8918500
    [Abstract] [Full Text] [Related]

  • 4. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I, Pearce R, Taghipour G, Goldstone AH.
    J Clin Oncol; 1997 Feb 01; 15(2):509-17. PubMed ID: 9053472
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 6. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
    [Abstract] [Full Text] [Related]

  • 7. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb 01; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 8. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT.
    J Clin Oncol; 2000 Dec 01; 18(23):3918-24. PubMed ID: 11099321
    [Abstract] [Full Text] [Related]

  • 9. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):467-72. PubMed ID: 10482929
    [Abstract] [Full Text] [Related]

  • 10. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P, Milpied N, Voillat L, Colombat P, Mahé B, Rapp MJ, Moreau A, Dupas B, Bulabois CE, Juge-Morineau N, Harousseau JL.
    Bone Marrow Transplant; 1998 Jun 01; 21(12):1193-6. PubMed ID: 9674850
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L.
    J Clin Oncol; 1997 Apr 01; 15(4):1617-23. PubMed ID: 9193361
    [Abstract] [Full Text] [Related]

  • 12. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH.
    J Clin Oncol; 1997 Jan 01; 15(1):5-10. PubMed ID: 8996118
    [Abstract] [Full Text] [Related]

  • 13. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 01; 10(3):186-91. PubMed ID: 20511163
    [Abstract] [Full Text] [Related]

  • 14. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E, Mahlamäki E, Nousiainen T.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):737-41. PubMed ID: 11042654
    [Abstract] [Full Text] [Related]

  • 15. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
    Bone Marrow Transplant; 1998 Feb 01; 21(4):383-9. PubMed ID: 9509973
    [Abstract] [Full Text] [Related]

  • 16. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG.
    Biol Blood Marrow Transplant; 1996 May 01; 2(2):76-85. PubMed ID: 9118302
    [Abstract] [Full Text] [Related]

  • 17. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD.
    Ann Oncol; 1998 Mar 01; 9(3):289-95. PubMed ID: 9602263
    [Abstract] [Full Text] [Related]

  • 18. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
    Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI.
    J Clin Oncol; 1998 Jan 01; 16(1):48-55. PubMed ID: 9440722
    [Abstract] [Full Text] [Related]

  • 19. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Rizzoli V.
    J Clin Oncol; 1998 Aug 01; 16(8):2796-802. PubMed ID: 9704732
    [Abstract] [Full Text] [Related]

  • 20. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG.
    J Clin Oncol; 1994 Dec 01; 12(12):2552-8. PubMed ID: 7989928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.